1090 related articles for article (PubMed ID: 34597941)
21. Immunogenicity and Adverse Effects of the 2-Dose BNT162b2 Messenger RNA Vaccine Among Liver Transplantation Recipients.
Davidov Y; Tsaraf K; Cohen-Ezra O; Likhter M; Ben Yakov G; Levy I; Levin EG; Lustig Y; Mor O; Rahav G; Ben Ari Z
Liver Transpl; 2022 Feb; 28(2):215-223. PubMed ID: 34767690
[TBL] [Abstract][Full Text] [Related]
22. Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls.
Hamm SR; Møller DL; Pérez-Alós L; Hansen CB; Pries-Heje MM; Heftdal LD; Hasselbalch RB; Fogh K; Madsen JR; Almagro Armenteros JJ; Knudsen AD; Poulsen JR; Frikke-Schmidt R; Hilsted LM; Sørensen E; Ostrowski SR; Harboe ZB; Perch M; Sørensen SS; Rasmussen A; Bundgaard H; Garred P; Iversen K; Nielsen SD
Front Immunol; 2022; 13():832501. PubMed ID: 35281023
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
Front Immunol; 2021; 12():690698. PubMed ID: 34276681
[TBL] [Abstract][Full Text] [Related]
24. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
[TBL] [Abstract][Full Text] [Related]
25. Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment.
Su E; S Fischer ; R Demmer-Steingruber ; Nigg S; Güsewell S; Albrich WC; Rothermundt C; Silzle T; Kahlert CR
ESMO Open; 2022 Oct; 7(5):100587. PubMed ID: 36156449
[TBL] [Abstract][Full Text] [Related]
26. Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay.
Kato H; Miyakawa K; Ohtake N; Go H; Yamaoka Y; Yajima S; Shimada T; Goto A; Nakajima H; Ryo A
J Infect Chemother; 2022 Feb; 28(2):273-278. PubMed ID: 34857462
[TBL] [Abstract][Full Text] [Related]
27. Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies.
Bergamaschi C; Pagoni M; Rosati M; Angel M; Tzannou I; Vlachou M; Darmani I; Ullah A; Bear J; Devasundaram S; Burns R; Baltadakis I; Gigantes S; Dimopoulos MA; Pavlakis GN; Terpos E; Felber BK
Front Immunol; 2022; 13():899972. PubMed ID: 35693807
[TBL] [Abstract][Full Text] [Related]
28. Durability of immune response after SARS-CoV-2 vaccination in patients with chronic liver disease.
Song R; Yang C; Li Q; Wang J; Chen J; Sun K; Lv H; Yang Y; Liang J; Ye Q; Gao Y; Li J; Li Y; Yan J; Liu Y; Wang T; Liu C; Zhu P; Wang F; Yin W; Xiang H
Front Immunol; 2023; 14():1200198. PubMed ID: 37398662
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study.
Puspitasari M; Sattwika PD; Hidayat ARP; Wijaya W; Wardhani Y; Intansari US; Kertia N; Purwanto B; Thobari JA
BMC Nephrol; 2023 May; 24(1):151. PubMed ID: 37248445
[TBL] [Abstract][Full Text] [Related]
30. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
[TBL] [Abstract][Full Text] [Related]
31. Humoral immune response to authentic circulating severe acute respiratory syndrome coronavirus 2 variants elicited by booster vaccination with distinct receptor-binding domain subunits in mice.
Jiang Y; Zhang H; Yu J; Huang D; Zhai L; Li M; Wang Y; Ren Z; Zou L; Zheng Z; Hu H; Zhang J; Zhang B; Zhao W; Yang X; Li B; Shen C
J Med Virol; 2022 Sep; 94(9):4533-4538. PubMed ID: 35614018
[TBL] [Abstract][Full Text] [Related]
32. Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals.
Fraley E; LeMaster C; Geanes E; Banerjee D; Khanal S; Grundberg E; Selvarangan R; Bradley T
BMC Med; 2021 Jul; 19(1):169. PubMed ID: 34304742
[TBL] [Abstract][Full Text] [Related]
33. Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review.
Notarte KI; Guerrero-Arguero I; Velasco JV; Ver AT; Santos de Oliveira MH; Catahay JA; Khan MSR; Pastrana A; Juszczyk G; Torrelles JB; Lippi G; Martinez-Sobrido L; Henry BM
J Med Virol; 2022 Jul; 94(7):2939-2961. PubMed ID: 35229324
[TBL] [Abstract][Full Text] [Related]
34. COVID-19 Severity, Cardiological Outcome, and Immunogenicity of mRNA Vaccine on Adult Patients With 22q11.2 DS.
Pulvirenti F; Mortari EP; Putotto C; Terreri S; Fernandez Salinas A; Cinicola BL; Cimini E; Di Napoli G; Sculco E; Milito C; Versacci P; Agrati C; Marino B; Carsetti R; Quinti I
J Allergy Clin Immunol Pract; 2023 Jan; 11(1):292-305.e2. PubMed ID: 36280136
[TBL] [Abstract][Full Text] [Related]
35. Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study.
Tamura T; Ninomiya K; Kubo T; Kuyama S; Tachibana S; Inoue K; Chikamori K; Kudo K; Ochi N; Harada D; Maeda Y; Kiura K
Thorac Cancer; 2022 Feb; 13(3):453-459. PubMed ID: 34964270
[TBL] [Abstract][Full Text] [Related]
36. A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study.
Lasagna A; Agustoni F; Percivalle E; Borgetto S; Paulet A; Comolli G; Sarasini A; Bergami F; Sammartino JC; Ferrari A; Zavaglio F; Arena F; Lilleri D; Secondino S; Falzoni M; Schiavo R; Klersy C; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
ESMO Open; 2021 Oct; 6(5):100272. PubMed ID: 34543863
[TBL] [Abstract][Full Text] [Related]
37. Mathematical modelling of the waning of anti-RBD IgG SARS-CoV-2 antibody titers after a two-dose BNT162b2 mRNA vaccination.
Cimas FJ; Torres J; Ontañón J; de Cabo C; Lozano J; Requena MÁ; Blas J; Rodríguez-García JL; Mas A; Solera J
Front Immunol; 2023; 14():1097747. PubMed ID: 36776854
[TBL] [Abstract][Full Text] [Related]
38. COVID-19 breakthrough infections and humoral immune response among BNT162b2 vaccinated healthcare workers in Malaysia.
Yang SL; Mat Ripen A; Leong CT; Lee JV; Yen CH; Chand AK; Koh K; Abdul Rahim NAB; Gokilavanan V; Mohamed NNEB; Sevalingam RKA; Sulaiman N; Ab Razak AKB; Mohd Nor NHB; Pong MK; Tai KY; Toh V; Woon YL; Peariasamy KM
Emerg Microbes Infect; 2022 Dec; 11(1):1262-1271. PubMed ID: 35412409
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the Serial Humoral Immune Response according to the Immunosuppressive Treatment after SARS-CoV-2 mRNA Vaccination.
Menjo H; Hasegawa M; Fujigaki H; Ishihara T; Minatoguchi S; Koide S; Hayashi H; Saito M; Takahashi K; Ito H; Yuzawa Y; Saito K; Tsuboi N
Intern Med; 2023 Dec; 62(23):3445-3454. PubMed ID: 37779074
[TBL] [Abstract][Full Text] [Related]
40. Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study.
Olariu TR; Ursoniu S; Marincu I; Lupu MA
Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946275
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
